Literature DB >> 8745399

Crystallographic determination of the structures of human alpha-thrombin complexed with BMS-186282 and BMS-189090.

M F Malley1, L Tabernero, C Y Chang, S L Ohringer, D G Roberts, J Das, J S Sack.   

Abstract

The crystallographic structures of the ternary complexes of human alpha-thrombin with hirugen (a sulfated hirudin fragment) and the small-molecule active site thrombin inhibitors BMS-186282 and BMS-189090 have been determined at 2.6 and 2.8 A. In both cases, the inhibitors, which adopt very similar bound conformations, bind in an antiparallel beta-strand arrangement relative to the thrombin main chain in a manner like that reported for PPACK, D-Phe-Pro-Arg-CH2Cl. They do, however, exhibit differences in the binding of the alkyl guanidine moiety in the specificity pocket. Numerous hydrophilic and hydrophobic interactions serve to stabilize the inhibitors in the binding pocket. Although PPACK forms covalent bonds to both serine and the histidine of the catalytic triad of thrombin, neither BMS-186282 nor BMS-189090 bind covalently and only BMS-186282 forms a hydrogen bond to the serine of the catalytic triad. Both inhibitors bind with high affinity (Ki = 79 nM and 3.6 nM, respectively) and are highly selective for thrombin over trypsin and other serine proteases.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8745399      PMCID: PMC2143347          DOI: 10.1002/pro.5560050205

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  8 in total

1.  Structure of the hirugen and hirulog 1 complexes of alpha-thrombin.

Authors:  E Skrzypczak-Jankun; V E Carperos; K G Ravichandran; A Tulinsky; M Westbrook; J M Maraganore
Journal:  J Mol Biol       Date:  1991-10-20       Impact factor: 5.469

2.  Human D-Phe-Pro-Arg-CH2-alpha-thrombin crystallization and diffraction data.

Authors:  E Skrzypczak-Jankun; T J Rydel; A Tulinsky; J W Fenton; K G Mann
Journal:  J Mol Biol       Date:  1989-04-20       Impact factor: 5.469

3.  Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty.

Authors:  E J Topol; R Bonan; D Jewitt; U Sigwart; V V Kakkar; M Rothman; D de Bono; J Ferguson; J T Willerson; J Strony
Journal:  Circulation       Date:  1993-05       Impact factor: 29.690

4.  Refined structure of the hirudin-thrombin complex.

Authors:  T J Rydel; A Tulinsky; W Bode; R Huber
Journal:  J Mol Biol       Date:  1991-09-20       Impact factor: 5.469

5.  Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty.

Authors:  A A van den Bos; J W Deckers; G R Heyndrickx; G J Laarman; H Suryapranata; F Zijlstra; P Close; J J Rijnierse; H R Buller; P W Serruys
Journal:  Circulation       Date:  1993-11       Impact factor: 29.690

6.  Kinetic and crystallographic studies of thrombin with Ac-(D)Phe-Pro-boroArg-OH and its lysine, amidine, homolysine, and ornithine analogs.

Authors:  P C Weber; S L Lee; F A Lewandowski; M C Schadt; C W Chang; C A Kettner
Journal:  Biochemistry       Date:  1995-03-21       Impact factor: 3.162

7.  Structure of a retro-binding peptide inhibitor complexed with human alpha-thrombin.

Authors:  L Tabernero; C Y Chang; S L Ohringer; W F Lau; E J Iwanowicz; W C Han; T C Wang; S M Seiler; D G Roberts; J S Sack
Journal:  J Mol Biol       Date:  1995-02-10       Impact factor: 5.469

8.  Highly selective tripeptide thrombin inhibitors.

Authors:  R T Shuman; R B Rothenberger; C S Campbell; G F Smith; D S Gifford-Moore; P D Gesellchen
Journal:  J Med Chem       Date:  1993-02-05       Impact factor: 7.446

  8 in total
  4 in total

1.  Structural basis for chemical inhibition of human blood coagulation factor Xa.

Authors:  K Kamata; H Kawamoto; T Honma; T Iwama; S H Kim
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-09       Impact factor: 11.205

2.  Hirunorms are true hirudin mimetics. The crystal structure of human alpha-thrombin-hirunorm V complex.

Authors:  G De Simone; A Lombardi; S Galdiero; F Nastri; R Della Morte; N Staiano; C Pedone; M Bolognesi; V Pavone
Journal:  Protein Sci       Date:  1998-02       Impact factor: 6.725

3.  The crystal structure of human alpha-thrombin complexed with LY178550, a nonpeptidyl, active site-directed inhibitor.

Authors:  N Y Chirgadze; D J Sall; V J Klimkowski; D K Clawson; S L Briggs; R Hermann; G F Smith; D S Gifford-Moore; J P Wery
Journal:  Protein Sci       Date:  1997-07       Impact factor: 6.725

4.  Reversible covalent direct thrombin inhibitors.

Authors:  Mohanram Sivaraja; Nicola Pozzi; Matthew Rienzo; Kenneth Lin; Timothy P Shiau; Daniel M Clemens; Lev Igoudin; Piotr Zalicki; Stephanie S Chang; M Angels Estiarte; Kevin M Short; David C Williams; Anirban Datta; Enrico Di Cera; David B Kita
Journal:  PLoS One       Date:  2018-08-02       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.